FindTrial
Sign In

COVID-19 and blood cancer registry

COVID-19 with Hematological Cancers Registry of India - CHCRI registry

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/04/032865
Enrollment
50
Registered
2021-04-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: C00-D49- Neoplasms

Interventions

None listed

Sponsors

Tata Memorial Hospital Mumbai
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Patients of ages above 18 years who have a current or previously diagnosed hematologic cancer within the past five years. 2)Diagnosed to have concomitant COVID-19 infection after 1stMarch 2020 through RT-PCR COVID-19 or antigen-based testing.

Exclusion criteria

Exclusion criteria: 1)Patients who are not on any treatment for hematologic cancer and are in remission formore than five years 2)Patients/family members unwilling to giving informed consent 3)Definitive diagnosis of hematologic cancer not made ante-mortem or post mortem

Design outcomes

Primary

MeasureTime frame
COVID-19 infection related mortality in patients with hematological malignanciesTimepoint: At Day 30 and 3 month.—

Secondary

MeasureTime frame
To analyse the characteristics pertaining to hematologic cancers and the impact of diagnosis of SARS-CoV-2 infection on the treatment of hematologic cancers.Timepoint: At day 30 and 3 month—

Countries

India

Contacts

Public ContactDr Lingaraj Nayak

Tata Memorial Hospital, Mumbai

lingarajnayak86@gmail.com9167294976

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026